"KLOW"
KPV + GHK-Cu + BPC-157 + TB-500 — GLOW plus KPV: the most ingredients, the least combined evidence.
Evidence tier C · Not approved in Canada · Community risk: high — four unverifiable doses in one vial.
C
What it is
KLOW is a community-named, usually premixed injectable blend of KPV + GHK-Cu + BPC-157 + TB-500 — GLOW plus KPV. It's positioned as the better base when inflammation is in the picture (rosacea, gut, post-procedure skin), and adds the single least-studied ingredient of the whole family to an already-unproven blend.
What People Use it For
• Skin, inflammation, gut, and recovery — the "anti-inflammatory upgrade" of GLOW.
• Sold premixed, as a finished four-peptide product.
What The Evidence Shows
KLOW stacks four Tier-C compounds, and KPV has essentially no human trials — so KLOW adds the ingredient with the least evidence of the entire family to a blend that already had none.
The combination has zero human trials. As with GLOW and Wolverine, every claim is inferred from thin single-compound data plus anecdote. The more ingredients in the vial, the more assumptions are stacked on top of each other.
Regulatory Status - Canada
No component is Health-Canada-approved. Premixed KLOW is unapproved and unverified regardless of label. US context: BPC-157, TB-500/thymosin β4, and KPV are among the peptides under FDA Pharmacy Compounding Advisory Committee review (July 23–24, 2026) — a US compounding-list matter that doesn't change Health Canada status.
Risks & Red Flags
• More ingredients = more unverifiable variables: four undisclosed doses in one vial, none confirmable, reactions un-attributable.
• Pro-angiogenic concern (BPC-157 / TB-500); copper load (GHK-Cu); KPV effects essentially uncharacterized in humans.
• Self-injection sterility and reconstitution-math error..
The Honest Bottom Line
KLOW is GLOW with one more unknown bolted on. Each ingredient you add to a vial multiplies what you can't verify — and KLOW's extra ingredient, KPV, is the least-studied of the whole set. So the "upgrade" is really a downgrade in how much you can know about what you're injecting. If you can't name the dose of any one component or trace a reaction to its cause, you're not treating inflammation — you're gambling on a four-way mix nobody has ever tested together.
How To Lower Your Risk
• The more compounds in a vial, the less you can know — KLOW is the clearest case for preferring single, verifiable compounds if using at all.
• Third-party identity + quantity testing is the minimum sourcing bar; "99% purity" confirms neither identity nor dose.
• Sterile technique; never share vials; watch for injection-site infection.
• Talk to a clinician — if the target is inflammation, that's a reason to get the cause diagnosed rather than blend-treated.
• Learn the slang glossary; be aware Glow/Klow swaps are documented, so the vial may not even be the blend you bought.
Sources
• Component evidence: BPC-157, TB-500, GHK-Cu, and KPV pages (this project); KPV human evidence essentially absent.
• Combination: no human trials identified.
• Mislabeling / Glow-Klow swaps: grey-market testing and pharmacist commentary (this project's community-discourse memo).
Substrate is an independent educational harm-reduction resource. It is not medical, legal, or regulatory advice, and it is not a substitute for a licensed clinician. Compounds discussed are largely unapproved in Canada; nothing here endorses their use. Confirm anything health-related with a qualified professional. Built by a medical-sciences student — not a seller and not a clinic.